A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

The 70‐gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy‐prognoSTics‐in‐breast‐cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 7...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2013-08, Vol.133 (4), p.929-936
Hauptverfasser: Drukker, C.A., Bueno‐de‐Mesquita, J.M., Retèl, V.P., Harten, W.H., Tinteren, H., Wesseling, J., Roumen, R.M.H., Knauer, M., Veer, L.J., Sonke, G.S., Rutgers, E.J.T., Vijver, M.J., Linn, S.C.
Format: Artikel
Sprache:eng
Schlagworte:
adjuvant systemic treatment
Adult
Biological and medical sciences
Breast cancer
Breast Neoplasms - pathology
Cancer
Chemotherapy
Early Detection and Diagnosis
Female
gene expression profiling
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Probability
prognosis prediction
Prospective Studies
Risk factors
Survival Rate
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The 70‐gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy‐prognoSTics‐in‐breast‐cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 70‐gene signature, which result was available for 427 patients (cT1–3N0M0). Adjuvant systemic treatment decisions were based on the Dutch CBO 2004 guidelines, the 70‐gene signature and doctors' and patients' preferences. Five‐year distant‐recurrence‐free‐interval (DRFI) probabilities were compared between subgroups based on the 70‐gene signature and Adjuvant! Online (AOL) (10‐year survival probability
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.28082